Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019
Open Access
- 2 May 2023
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 13 (5) , 787
Abstract
Cardiovascular diseases (CVDs) are the main contributors to global morbidity and mortality. Major pathogenic phenotypes of CVDs include the development of endothelial dysfunction, oxidative stress, and hyper-inflammatory responses. These phenotypes have been found to overlap with the pathophysiological complications of coronavirus disease 2019 (COVID-19). CVDs have been identified as major risk factors for severe and fatal COVID-19 states. The renin–angiotensin system (RAS) is an important regulatory system in cardiovascular homeostasis. However, its dysregulation is observed in CVDs, where upregulation of angiotensin type 1 receptor (AT1R) signaling via angiotensin II (AngII) leads to the AngII-dependent pathogenic development of CVDs. Additionally, the interaction between the spike protein of severe acute respiratory syndrome coronavirus 2 with angiotensin-converting enzyme 2 leads to the downregulation of the latter, resulting in the dysregulation of the RAS. This dysregulation favors AngII/AT1R toxic signaling pathways, providing a mechanical link between cardiovascular pathology and COVID-19. Therefore, inhibiting AngII/AT1R signaling through angiotensin receptor blockers (ARBs) has been indicated as a promising therapeutic approach to the treatment of COVID-19. Herein, we review the role of AngII in CVDs and its upregulation in COVID-19. We also provide a future direction for the potential implication of a novel class of ARBs called bisartans, which are speculated to contain multifunctional targeting towards COVID-19.Keywords
This publication has 179 references indexed in Scilit:
- Interferon‐γ biphasically regulates angiotensinogen expression via a JAK‐STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cellsThe FASEB Journal, 2012
- Macrophage Polarization by Angiotensin II-Type 1 Receptor Aggravates Renal Injury-Acceleration of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsVascular Health and Risk Management, 2011
- Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathwayAmerican Journal of Physiology-Cell Physiology, 2011
- Angiotensin II receptors and drug discovery in cardiovascular diseaseDrug Discovery Today, 2011
- Losartan Decreases p42/44 MAPK Signaling and Preserves LZ+ MYPT1 ExpressionPLOS ONE, 2009
- Anti-Inflammatory Effects of Angiotensin Receptor Blockers in the Brain and the PeripheryCellular and Molecular Neurobiology, 2009
- IL-6 and Serum Amyloid A Synergy Mediates Angiotensin II–Induced Muscle WastingJournal of the American Society of Nephrology, 2009
- Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathyNephrology Dialysis Transplantation, 2008
- Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cellsExperimental Eye Research, 2007